The Arnold L. Johnson Lectureship in Cardiology – held 23 times since 1995 – returned this week with the esteemed Dr. Bertram Pitt, Professor of Medicine Emeritus, University of Michigan, lecturing on “new opportunities for mineralocorticoid receptor antagonists (MRAs) alone and in combination in cardiorenal disease.”
The event was a happy return to in-person at the home of PHRI – the David Braley Cardiac Vascular Stroke Research Institute in Hamilton, Ontario.
The lectureship was hosted by PHRI Senior Scientist Jeff Healey, on behalf of the Cardiology Division at McMaster University (of which he is Director), PHRI Executive Director Salim Yusuf and PHRI Scientist Harriette Van Spall.
The excellent turnout for the lectureship was matched the following day, October 4th, when Dr. Pitt gave Cardiology Grand Rounds on “CV outcomes in diabetes – does SGLT1/2i offer benefit over SGLT2i?
Dr. Pitt is currently chairman of the steering committee of the NHLBI TOPCAT trial; co-chairman of the Emphasis-HF trial, chairman of Break- DHF, co-chairman of STOP-CKD, co-chairman of Exceed, co-chairman of Escape-SHF and Escape-DHF, chairman of a study evaluating the role of an aldosterone synthase inhibitor in patients with HF, and a member of the executive committee of the Accomplish trial.
He has been awarded the James B. Herrick Award by the Council of Clinical Cardiology of the American Heart Association and has been elected to the Society of Scholars of the Johns Hopkins University. He obtained his MD degree from the University of Basel in Switzerland, and completed a fellowship in cardiology at the Johns Hopkins University School of Medicine and remained on the faculty there until he left to direct the division of cardiology at the University of Michigan.